2022
Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomesAssociation of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer
Patel H, Srivastava A, Kim S, Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer. Journal Of Urology 2022, 207: 1057-1066. PMID: 34978466, DOI: 10.1097/ju.0000000000002369.Peer-Reviewed Original ResearchConceptsPrimary retroperitoneal lymph node dissectionRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsLymph node countLymph nodesOverall survivalTherapeutic implicationsTesticular nonseminomatous germ cell tumorsFive-year OS ratesHigher lymph node countLymph node-positive diseasePrimary retroperitoneal lymphadenectomyClinical stage INational Cancer DatabaseLymph node dissectionNode-positive diseaseKaplan-Meier methodNonseminomatous testicular cancerCS IGerm cell tumorsLogistic regression analysisNode countImproved OSNode dissectionRetroperitoneal lymphadenectomy
2019
DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome
Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaDisease-free survivalAdvanced clear cell renal cell carcinomaDDR pathway alterationPathway alterationsLocalized Clear Cell Renal Cell CarcinomaDecreased disease-free survivalTCGA databaseShorter disease-free survivalCopy number alterationsTherapeutic agentsCox regression analysisT3-4 diseaseClear-Cell RenalRenal cell carcinomaDDR pathwaysPresence of mutationsT3a diseaseNeoadjuvant therapyOverall survivalPoor outcomeCell carcinomaCommon subtypeDisease progressionKidney cancer
2016
Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice
Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice. Clinical Genitourinary Cancer 2016, 14: e617-e622. PMID: 27188968, DOI: 10.1016/j.clgc.2016.04.010.Peer-Reviewed Original ResearchConceptsExtracapsular extensionProstate cancerRadical prostatectomyMp-MRINegative predictive valuePositive predictive valuePredictive valuePartin tablesMultiparametric magnetic resonance imagingNerve-sparing approachPreoperative mp-MRID'Amico risk groupsLarge referral centerHigh-risk groupDatabase of menMagnetic resonance imagingReferral centerStaging modalitiesD'Amico criteriaFusion biopsyOverall prevalenceRisk groupsMultiparametric MRISurgeon's decisionResonance imaging
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsRefining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusIncreased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma
Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma. Journal Of Urology 2015, 194: 1441-1448. PMID: 25796113, DOI: 10.1016/j.juro.2015.03.078.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternCarcinoma, Renal CellCell Line, TumorDisease ProgressionFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisReal-Time Polymerase Chain ReactionReceptors, AndrogenRetrospective StudiesRNA, NeoplasmTime FactorsYoung AdultConceptsRenal cell carcinomaAndrogen receptor mRNA expressionReceptor mRNA expression levelsCancer-specific survivalCell carcinomaCell carcinoma cell linesReceptor mRNA expressionHuman renal cell carcinoma cell linesRenal cell carcinoma cell linesAndrogen receptorMRNA expression levelsSpecific survivalCarcinoma cell linesMultivariate Cox regression analysisLocalized Renal Cell CarcinomaMRNA expressionT2 renal cell carcinomaCell linesPathological stage T1Androgen receptor expressionCox regression analysisKaplan-Meier estimatesReceptor-positive cell linesChain reactionPositive renal cell carcinomas
2014
Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH
Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals Of Surgical Oncology 2014, 22: 2439-2445. PMID: 25348783, DOI: 10.1245/s10434-014-4194-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorCalgranulin ACalgranulin BCase-Control StudiesFollow-Up StudiesHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingNucleic AcidsPrognosisProstatic HyperplasiaProstatic NeoplasmsReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSurvival RateConceptsS100A8/A9CAP patientsAcid levelsNucleic acid levelBPH tissueProstate cancerS100A8/A9 expressionBenign prostatic hyperplasia tissuesRecurrence-free timeProstatic hyperplasia tissuesUrinary nucleic acidsBPH patientsIndependent predictorsTransurethral resectionAggressive diseaseChronic inflammationPoor prognosisPrognostic valueTransurethral prostatectomyProstatectomy patientsBiochemical recurrencePrognostic markerS100A9 expressionA9 expressionImmunohistochemical stainingCytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
FAIENA I, SINGER E, PUMILL C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). International Journal Of Oncology 2014, 45: 2193-2198. PMID: 25340386, PMCID: PMC4215584, DOI: 10.3892/ijo.2014.2656.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerProstate cancerMetastatic diseaseSystemic therapyRadical prostatectomyPotential oncologic benefitsDefinitive local therapyPrior radical prostatectomyLow-stage cancersNew surgical paradigmOncologic benefitAcceptable morbidityAdvanced diseaseMetastatic settingLocal therapySimilar morbidityCancer deathKidney cancerStage cancerBetter survivalSurgical paradigmPatientsCancerPotential benefitsTherapyDecreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma
Ha Y, Lee G, Kim Y, Kwon S, Choi S, Kim T, Kwon T, Yun S, Kim I, Kim W. Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma. World Journal Of Surgical Oncology 2014, 12: 288. PMID: 25227434, PMCID: PMC4176564, DOI: 10.1186/1477-7819-12-288.Peer-Reviewed Original ResearchAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, PapillaryCarcinoma, Renal CellCase-Control StudiesFemaleFollow-Up StudiesHumansKidney NeoplasmsMaleMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRNA, MessengerSelenium-Binding ProteinsSurvival RateYoung AdultNovel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2
Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersCarrier ProteinsEndopeptidasesFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessNeoplasm StagingPlatelet Glycoprotein GPIb-IX ComplexPredictive Value of TestsRegression AnalysisRisk FactorsROC CurveUbiquitin ThiolesteraseUrinary Bladder NeoplasmsConceptsCancer-specific survivalCancer-specific deathBladder cancer patientsHigh expression groupExpression of USP18MIBC patientsCancer patientsExpression groupMuscle-invasive bladder cancer patientsCancer-specific survival ratesInvasive bladder cancer patientsMuscle-invasive bladder cancerLonger cancer-specific survivalMultivariate Cox regression analysisCox regression analysisInvasive bladder cancerSignificant risk factorsReliable prognostic markersMRNA expression levelsSurvival-related genesOverall survivalValidation cohortOriginal cohortLonger survivalPredicting SurvivalThe predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer
Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology Seminars And Original Investigations 2014, 32: 458-465. PMID: 24411789, DOI: 10.1016/j.urolonc.2013.10.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBCG VaccineCarcinoma, Transitional CellFemaleFollow-Up StudiesGenotypeGlutathione TransferaseHumansMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPolymorphism, GeneticPrognosisRisk FactorsSmokingSurvival RateUrinary Bladder NeoplasmsConceptsNon-muscle invasive bladder cancerGSTT1-positive genotypeInvasive bladder cancerPrimary non-muscle invasive bladder cancerBCG failureBladder cancerPredictive valueInduction therapyIndependent predictorsHigh riskBacillus Calmette-Guérin induction therapyNull genotypeMultivariate logistic regression analysisMultivariate logistic regression modelBCG induction therapyInduction BCG therapySingle induction courseDisease-free survivalGlutathione S-transferase muKaplan-Meier analysisHigh-risk groupKaplan-Meier estimatesEarly responseLogistic regression analysisGSTT1 null genotype
2013
Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts
Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts. Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. PMID: 24377625, DOI: 10.7314/apjcp.2013.14.11.6913.Peer-Reviewed Original ResearchConceptsBody mass indexHigh Gleason scoreGleason scoreProstate cancerT stageRadical prostatectomyPreoperative prostate-specific antigen levelProstate cancer treatment strategiesProstate-specific antigen levelMean body mass indexKorean prostate cancer patientsMean preoperative PSAWorse disease characteristicsAdvanced prostate cancerPathological T stageHigher T stageProstate cancer patientsHigher PSA valuesMalignant prostate cancerCancer treatment strategiesPreoperative PSAMass indexProstate sizePSA testPSA valuesComprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy
Woo S, Kang D, Ha Y, Salmasi A, Kim J, Lee D, Kim W, Kim I. Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy. Journal Of Endourology 2013, 28: 172-177. PMID: 23987521, DOI: 10.1089/end.2013.0304.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyPotency ratesNeurovascular bundleRadical prostatectomyPotency recoveryBilateral preservationYounger ageOverall potencyPhosphodiesterase type 5 inhibitorsBaseline erectile functionPreoperative potency statusSexual Health InventoryDatabase of patientsType 5 inhibitorsFunction 12 monthsProstate cancer patientsRecovery of potencySexual function outcomesPDE-5 inhibitorsOverall potency rateMultivariate regression analysisPotency statusPreoperative potencyErectile functionIndependent predictorsFactors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey
Kim J, Ha Y, Jeong S, Kim S, Kim W, Jang T, Kim I. Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey. Prostate Cancer And Prostatic Diseases 2013, 16: 341-345. PMID: 23917307, PMCID: PMC5767467, DOI: 10.1038/pcan.2013.24.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyPatient-perceived satisfactionProstate Cancer Index Composite surveyUrinary botherEPIC scoresRadical prostatectomyIndependent factorsLongitudinal changesOverall satisfactionEPIC questionnaireProstate cancerSame patientGroup 1Optimal managementPatientsRecovery periodLinear mixed modelsProstatectomyComposite surveyMonthsDomain subscalesMenScoresMixed modelsGroupDetailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study
Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padAnterior fat padLymph node metastasisMetastatic diseaseLymph nodesNode metastasisFat padPathological analysisMost patientsConcomitant pelvic lymph node dissectionPelvic lymph node dissectionBiochemical recurrence-free survivalAdjuvant/salvage therapyLymph node dissectionCharacteristics of patientsHigh-risk featuresTertiary care centerRecurrence-free survivalMulti-institutional studyPerioperative characteristicsSalvage therapyAdjuvant therapyNode dissectionAndrogen ablationClinical outcomesIncidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance
Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance. Urologia Internationalis 2013, 90: 301-305. PMID: 23391718, DOI: 10.1159/000345292.Peer-Reviewed Original ResearchConceptsGleason score 3Prostate cancerRadical prostatectomyActive surveillanceScore 3Positive coresIncidence of upstagingPrediction of upgradingPSA cutoff levelPreoperative PSA levelUpstaging ratePSA levelsCancer involvementClinical stageNeedle biopsyUpstagingPatientsCutoff levelBiopsyMarginal associationIncidenceOverall rateCancerSurveillanceProstatectomy
2012
Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer
YUN S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal Of Oncology 2012, 41: 1871-1878. PMID: 22961325, DOI: 10.3892/ijo.2012.1622.Peer-Reviewed Original ResearchConceptsBladder cancerCell-free miRNAsMiR-200aMiR-145Transitional cell carcinomaBladder cancer patientsNon-cancer controlsHealthy normal controlsMiR-145 levelsMiR-200a levelsCell-free microRNAsNMIBC recurrenceIndependent predictorsClinicopathological featuresCell carcinomaCancer patientsPrognostic biomarkerUrinary bladderHigh riskNoninvasive biomarkersNormal controlsAccurate biomarkersMultivariate analysisPatientsCancerTranscriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressivenessRas Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer
Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clinical Genitourinary Cancer 2012, 10: 114-120. PMID: 22382007, DOI: 10.1016/j.clgc.2011.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Transitional CellChildDNA MethylationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosisPromoter Regions, GeneticProportional Hazards ModelsTumor BurdenTumor Suppressor ProteinsUrinary Bladder NeoplasmsYoung AdultConceptsRecurrent nonmuscle invasive bladder cancerNonmuscle invasive bladder cancerMuscle-invasive bladder cancerInvasive bladder cancerPrimary BC tissuesCox regression analysisBladder cancerPrognostic markerRASSF1A methylationRASSF1A hypermethylationIndependent predictorsBC tissuesMultivariate Cox regression analysisCancer progressionKaplan-Meier analysisAdvanced tumor stagePromising prognostic markerPromoter hypermethylationPotential prognostic markerRegression analysisRASSF1A promoter hypermethylationMethylation-specific polymerase chain reactionClinicopathologic featuresPrognostic significanceKaplan-Meier